Background. This study addressed the need for heparin administration to be continued for more than 24 hours after coronary thrombolysis with recombinant tissue-type plasminogen activator (rt-PA).
in particular is not clear. Heparin may increase the risk of bleeding complications after rt-PA administration. 9 As a result, a series of investigations on heparin and rt-PA were recently conducted. One published report showed that heparin administered at the same time as rt-PA had no significant additional effect on coronary artery patency at 90 minutes. 10 Two reports have indicated that heparin given in the period immediately after rt-PA will improve coronary artery patency.11,12 A recently completed international study showed no advantage in patient survival or reinfarction for heparin administration (12,500 units b.i.d. s.c.) starting 12 hours after thrombolytic therapy. 13 In the current trial, we administered an intravenous bolus of heparin as the infusion of rt-PA was begun, and when the rt-PA infusion was finished, we immediately began an intravenous infusion of heparin. We then assessed the need for heparin administration to continue after the first 24 hours after rt-PA administration by comparing its continued intravenous administration with an oral anti-platelet regimen of aspirin and dipyridamole.
Patient Selection
Patients 75 years old or less with suspected acute myocardial infarction were included in the trial if they had no prior history of myocardial infarction, were admitted to the hospital within 4 hours of symptom onset, had cardiac pain of typical character and location, and if the electrocardiogram showed ST segment elevation in two or more leads (>2 mm in suspected anterior infarction or >1 mm in suspected inferior infarction). Patients were excluded from the trial if they had at least one contraindication to thrombolytic therapy, such as previous cerebrovascular disease, active peptic ulceration or history of gastrointestinal hemorrhage, recent trauma, recent surgery, or hypertension. After informed consent was obtained, patients were administered rt-PA and heparin. rt-PA and Heparin Infusion rt-PA (Boehringer Ingelheim Pty. Ltd. Australia) was administered as a 10-mg bolus i.v. followed by a 50-mg infusion in the next hour and by 20 mg/hr during the subsequent 2 hours. Heparin 5,000 units i.v. was administered at the start of the rt-PA infusion, and after the infusion, heparin was continued in a dose of 1,000 units/hr for an additional 24 hours. Global ejection fraction and regional wall motion were measured both by the radial coordinate method of Rickards et al" and the long-axis chordal method of Sheehan et al. 15 Systolic and diastolic ventricular silhouettes were traced in two independent cycles that were free of ventricular ectopy. Ventriculograms were considered unsuitable for analysis when the entire outline of the ventricle could not be displayed.
Trial Administration and Ethical Supervision
The overall conduct of the trial was supervised by a management committee on which was represented the senior investigators from each participating center, the director of the National Heart Foundation, and a representative of Boehringer Ingelheim. The data from the trial were monitored by a data monitoring and ethics committee that received regular reports on the progress of the trial from an independent statistician.
Data Management
Data were forwarded from each center to the coordinating center. The data base was managed by the dBase III system and analyzed by use of PC-SAS in the Department of Cardiovascular Medicine of the Sir Charles Gairdner Hospital and the Unit of Clinical Epidemiology of the University of Western Australia.
Results
During the course of the trial (from February 1988 to December 1988), 1,464 patients with suspected acute myocardial infarction were admitted to the participating centers. Of these patients, 941 did not fulfill the inclusion criteria because of previous infarction, delays in excess of 4 hours, atypical chest pain, or insufficient electrocardiographic criteria. The remaining 523 patients fulfilled all inclusion criteria, but 265 had one or more exclusion criteria, predominantly a contraindication to thrombolytic therapy. Of these, 17 patients were eligible but did not enter the trial because they withheld informed consent or because the admitting physician did not agree to the patients' entering the trial. A total of 241 patients received rt-PA and then heparin for 24 hours. Of these, 202 patients were randomized, 103 had their regimen changed to oral aspirin and dipyridamole, and 99 continued intravenous heparin therapy. Thirty-nine patients were not randomized. The reasons for nonrandomization were death (nine patients), bleeding complications (six), major cardiac complications (two), cerebrovascular accidents (two, one of which was fatal), transient cerebral ischemic attacks (two), protocol violations (14) , and exclusion at the supervising physician's discretion (five). Overall, there were 16 in-hospital deaths (6.6%) in the 241 patients who received rt-PA.
Results were analyzed with the intention-to-treat principle. Seven patients in the aspirin and dipyridamole group had their trial medications stopped and were treated with anticoagulants because of proven apical left ventricular thrombus (one patient), headaches attributed to dipyridamole (one), recurrent chest pain (four), and medication error (one). Heparin therapy was discontinued in three patients in the heparin group because of anticoagulant complications.
Baseline characteristics in the two groups of patients were similar (Table 1) , and the severity of infarction assessed by enzyme and electrocardiographic criteria was similar. There was a similar proportion of patients with non-Q wave infarction in the two groups (six of 41 versus three of 38 in the anterior-anterolateral infarction subset and eight of 54 versus six of 51 in the inferior infarction subset). During the period of hospital treatment after randomization, there was one stroke (14 days after infarction, nonhemorrhagic on computed tomography scan) in the aspirin and dipyridamole group and none in the heparin group. Other major events (death and reinfarction) in the two groups are summarized in Table 2 . There was an increased number of events in the heparin group compared with that in the aspirin and dipyridamole group, but none of these were significant. Overall, there were 10 major events in the heparin group and five in the aspirin and dipyridamole group (p=0.09). The pattern of bleeding complications was similar in the two groups (Table 3 ). There were more cases of significant phlebitis of the intravenous site in the heparin group than in the aspirin and dipyridamole group (p=0.15). One patient in the heparin group developed thrombocytopenia (minimum platelet count, 120,000/ml).
The overall pattern of chest pain indicative of myocardial ischemia after infarction was similar in the two groups (Table 3) , and there were no differences in the timing of these episodes (Figure 1) . Overall, 196 patients underwent coronary angiography at 7-10 days, 95 in the heparin group and 101 in the aspirin and dipyridamole group. Reasons for failing to undergo coronary angiography at 7-10 days were death (five patients) and infection in the arm due to phlebitis (one).
The angiographic findings concerning the infarctrelated artery are summarized in Figures 2 and 3 . The grades of narrowing of the infarct-related artery averaged on two views are subdivided into five groups in Figure 2 . There were no significant differences in the distribution of incomplete occlusions; the number of patients with total occlusion was similar in the two groups: 19 of 95 (20.0%) in the heparin group and 20 of 101 (19.8%) in the aspirin and dipyridamole group. The degree of occlusion in the incompletely occluded infarct-related arteries was almost identical. In the heparin group, 76 patients had incomplete occlusion of 69±-2%, and in the aspirin and dipyridamole group, 81 patients had incomplete occlusion of 67+2%. Figure 3 shows the TIMI (Thrombolysis in Myocardial Infarction study) flow rates in the two groups showing that there was no difference in the distribution of TIMI flow rates in the infarct-related arteries in the two groups.
The left ventricular ejection fractions calculated from the contrast ventriculogram at the time of cardiac catheterization are shown in Table 4 ; there were no differences between the groups. The data for radionuclide estimates of left ventricular ejection fraction in the two groups are also shown in Table 4 . There were no differences in the two groups in ventricular ejection fractions measured on day 2.
There was a slight improvement in left ventricular ejection fractions at 1 month in both groups compared with day 2, but there were no differences between groups. Right ventricular ejection fractions showed a similar pattern. Patients with both Q wave and non-Q wave infarctions were combined in the ventriculographic analyses because conclusions from the analysis of the combined groups were not different from those of the separate groups. The APTT in the heparin group is summarized in Figure 4 , which shows that the mean APTT levels were maintained within the therapeutic range of 2-2.5 times normal. onstrated a more effective antithrombotic regimen after rt-PA. However, the major concern of our study was to determine whether continued heparin therapy was necessary. We would be concerned about the potential for hemorrhage, particularly intracranial, with a combined full-dose heparin and antiplatelet regimen. The report from the European cooperative study group17 showed that when heparin was continued in full dosage for 10-21 days in combination with aspirin the cerebral hemorrhage rate was 1.4%, which is considerably higher than that reported in other studies using less-aggressive antithrombotic regimens after rt-PA.
A limitation of our study is the potential for a type II error. Whether the addition of dipyridamole to aspirin was necessary is not clear from our results. Although this is an antiplatelet regimen that has been effective in several clinical situations, no clear advantage over therapy with aspirin alone has been shown. 18 Our intention was to compare the need for heparin with a potent antiplatelet regimen, but this trial was designed primarily to examine the need to continue heparin administration after 24 hours rather than establish the most appropriate antiplatelet regimen for continued antithrombotic therapy. The ISIS II trial has shown convincingly that the addition of aspirin to streptokinase will improve the survival and reinfarction rate (from 3.7% to 1.8%, p<0.001) of patients with suspected acute myocardial infarction.'6 Although the experience of thrombolysis with streptokinase is not directly applicable to that with rt-PA, the ISIS II findings suggest that oral aspirin is a highly effective antiplatelet regimen as an adjunct to thrombolytic treatment.
The main rationale for antithrombin anticoagulant therapy with heparin after thrombolytic therapy is the prevention of coronary reocclusion and reinfarction. With streptokinase, the meta-analysis of Yusuf et al '9 in 1985 all" studied the patency of the infarct-related artery at an average of 55 hours and showed that rt-PA alone resulted in patency in 44% of patients (n=41), whereas rt-PA combined with heparin resulted in patency in 71% (n=42). Hsia et al12 used a very low dosage of aspirin (80 mg/day) in comparison with heparin (1,000 units/hr) and subsequently titrated the dosage of heparin to achieve an APTT of 1-1.5 times the control value for 7 days; they showed that the early use of heparin had an advantage in patency of the infarct-related artery at 7-24 hours (82% in the heparin-treated group and 52% in the aspirin-treated group, p<0.0001). The two studies together strongly confirm a role for heparin early after thrombolysis with rt-PA. The International Study Group'3 examined the role of heparin on outcome after thrombolytic therapy and showed no benefit when heparin was given in a dosage of 12,500 units b.i.d. s.c., starting 12 hours after administration of rt-PA. The results of that study would be consistent with those of the present study, that is, that late administration of heparin confers no benefit. However, as mentioned earlier, our study did not address the issue of whether heparin or other antithrombin agents combined with antiplatelet agents would be more beneficial than either alone.
From this trial, we conclude that intravenous heparin therapy can be stopped at 24 hours after the administration of rt-PA and that oral regimens of antiplatelet agents can be substituted for heparin without any clinically significant adverse effects on coronary artery patency, left ventricular function, or clinical outcome. The following approach for adjunctive antithrombotic therapy with rt-PA can be synthesized from this and other recently completed clinical trials: Heparin may not be necessary before the administration of rt-PA10 because it does not improve patency at 90 minutes. However, it should be administered immediately after rt-PA and continued for 24 hours because it does improve patency.11,12 Thereafter, it can be stopped and replaced with an oral regimen of aspirin or other oral regimens of antiplatelet agents because the present study has shown no advantage in continuing heparin after 24 hours.
